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take into account confidential discounts under patient access schemes. Finally, 
the threshold probability of cost effectiveness seems to lie between 30% and 60%.
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Objectives: Multi criteria decision analysis (MCDA) aims to support decision-mak-
ing where decisions are based on multiple criteria. In disciplines like engineering 
and environmental policy, MCDA is widely accepted and routinely used. The use of 
MCDA in HTA priority setting and reimbursement decisions is growing, but mostly 
limited to research projects. A factor that might influence acceptance is a perceived 
difficulty to value an MCDA’s outcome when its inputs and outputs contain uncer-
tainties. When this is the case, decision makers might not feel confident in accept-
ing or rejecting its outcome. The objective of this study is to systematically review 
how parameter uncertainty is taken into account in value-based MCDA methods 
in general, and to discuss which of the approaches is appropriate for the setting of 
reimbursement decision making in health care. MethOds: A systematic literature 
review was conducted using the Scopus database. Found abstracts were categorized 
by MCDA method used. Then, themes and families of methods were identified by 
two independent reviewers. Selected full text articles were read to identify methodo-
logical details. Results: The search strategy identified 635 abstracts, mostly from 
engineering and environmental journals and only 1.6% in health journals. Identified 
themes were fuzzy set theory (n= 223), probabilistic framework (n= 68), deterministic 
sensitivity analysis (n= 140), Dempster-Shafer theory (n= 14), Bayesian framework 
(n= 7) and Grey theory (n= 8). A large number of papers considered the Analytic 
Hierarchy Process in combination with fuzzy set theory (n= 155). cOnclusiOns: 
In the health literature there is little attention for parameter uncertainty. Methods 
to deal with parameter uncertainty in MCDA must strike a balance between com-
prehensibility and understandability. Several complex methods are developed for 
parameter uncertainty, but there seems to be a gap between the theory and the 
implementation of those methods. For simple applications, methods like deter-
ministic sensitivity analysis are likely to be sufficient.
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Objectives: To investigate quantitatively, if and to which extent the German 
Arzneimittelmarkt-Neuordnungs-Gesetz (AMNOG) delays market access of phar-
maceuticals. Secondary objective was to potentially identify predictors for access 
delay. MethOds: All AMNOG assessment procedures that were completed at the 
level of the joint federal committee (G-BA) by May 15 2013 were included (web-
site www.g-ba.de). Time delay to dossier submission was calculated between the 
approval date of the European Medicines Agency (EMA) and the mandatory AMNOG 
dossier submission date. Submission date usually occurs when pharmaceuticals are 
made available and is decided upon by the manufacturer. We also included in the 
analysis the ordinal level classification and evidence certainty level for each product 
as assessed by Institute for Quality and Efficiency in Health Care (IQWiG) and G-BA 
as well as the ATC code. Results: In n= 17 (49%) of N= 35 investigated pharmaceu-
ticals a small time delay greater than 1.1 months (which is usually feasible) after 
EMA approval was observed, but only 20% had a delay > 2 months. A negative cor-
relation existed between the amount of time delay to dossier submission and the 
benefit level outcome as assessed by IQWIG (r= -0.258, n.s.) and the final result by 
G-BA (r= -0.484, p= 0.003). Benefit assessment outcomes between IQWiG and G-BA 
were correlated moderately with r= 0.442 (p< 0.008). For both, IQWiG (r= 0.841) and 
G-BA (r= 0.773) certainty of evidence correlated highly with the benefit level out-
come. cOnclusiOns: This analysis highlights the impact of AMNOG on the market 
access of pharmaceuticals in Germany. Overall, only small time delays existed for 
most products. Time delay in market access correlated significantly with a nega-
tive assessment of additional benefit by G-BA. Evidence certainty clearly correlated 
with benefit outcomes.
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Objectives: In Scotland, drug reimbursement is predominantly based on cost-
effectiveness in contrast to the corresponding German AMNOG process. The study 
compares the reimbursement and pricing process in Germany (AMNOG), as reformed 
in 2011, and Scotland (SMC) based on reimbursement assessments. MethOds: All 
AMNOG and SMC appraisal decisions made in 2011-2012 were identified. Matching 
AMNOG-SMC cases were found and compared in terms of final appraisal decision 
and rationale. Results: For 2011-2012, forty-one AMNOG cases over 60 subgroups 
and 193 SMC cases were identified; twenty five matching cases were compared 
as these were assessed by both organizations. Regarding these 25 cases, AMNOG 
deemed ten cases demonstrated no additional benefit, in two cases the additional 
benefit was unquantifiable, slight benefit was acknowledged in seven cases and 
in six there were significant benefits. Based on the benefit assessment the negoti-
ated price rebates ranged from 4.7% to 70.7% based on manufacturer set price. No 
restrictions to subgroups were opposed to any reimbursement decision. The SMC 
reimbursed 18 products (72%), of which four were restricted to a certain population 
due to cost-effectiveness. SMC rejected 7 cases (28%) based on weak economic evi-
Objectives: To investigate the problem of pricing and reimbursement of pharma-
ceuticals in Iran. A large amount of country’s Health care expenditures, including 
insurance organizations’ expenses, are spent for pharmaceutical products. However, 
the high amount of capital spent by the users for purchasing pharmaceuticals 
indicates a serious flaw in the system. As will be shown, this flaw is due to the struc-
tures, policies, and regulations of Iranian medical insurance system. MethOds: 
This is a descriptive study and, therefore, ethnographic site and fieldwork were used 
as the main source of information. Furthermore, information on the Internet and 
several Iranian online databases has been used for comparison purposes. Results: 
Ministry of Health and Medical Education (MOHME) is the main responsible body 
for pharmaceuticals in Iran. However, different government organizations such 
as Ministry of Commerce, the Central Bank of Iran, and National Industries 
Organizations are involved in policy-making in this sector. MOHME decides how 
to allocate governmental supports and foreign currency quotas, to various related 
industries. This is done due to the fact that MOHME decides which pharmaceuti-
cals should be covered and distributed in the country. However, prices are set by 
insurance organizations due to their bargaining power over MOHME. Insurance 
companies pay approximately 70-90% of the final price of a product. However, for 
purchasing expensive products, confirmation from insurance companies is needed. 
The reimbursed price is set at the level of the lowest priced equivalent on the mar-
ket. cOnclusiOns: These flaws and loopholes arise because of system’s negligence 
on research and development methods and, therefore, lack of standard regulations 
on reimbursement decisions and priority settings. Inflexible profit margins for dif-
ferent products with different unit costs, incomplete support for vulnerable groups 
and patients with chronic diseases, and absence of rational pharmaceutical usage 
campaigns can be named as other major problems.
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Objectives: Personalized health care (PHC) is a treatment model that customizes 
health care based on biomarker-based prediction of likely response. It is increas-
ingly being prioritized by politicians and payers—one recent example is the pub-
lished strategy plan by the German Federal Ministry of Education and Research. 
A key policy question remains whether health care systems and health tech-
nology assessment (HTA) bodies are adequately prepared evaluating these new 
treatment options. MethOds: Existing HTA evaluation methods for therapies in 
France, Germany, and the UK were reviewed with respect to the applicability to 
PHC products based on information provided by decision-making bodies and the 
literature. Results: Current HTA evaluation methods being applied to medical 
therapies, in general, need to be modified when applied to PHC. For example, tra-
ditional benefit evaluations that require randomized clinical trials are standard 
but cannot always be fulfilled in PHC. Furthermore, combined benefit assessments 
for typical PHC treatment—e.g., a pharmaceutical combined with a diagnostic 
test—lack experience about appropriate evaluation methods to use. Today, decison 
makers and manufacturers rarely make use of the opportunity to re-assess or for 
joint evidence generation. Finally, reimbursement for PHC is inflexible and does 
not fully reflect the value of targeting, including the reduction in uncertainty and 
greater appropriate use. Among these three, the UK seems the most open to PHC 
funding. HTA in France and Germany does not recognize the special economic and 
evidence features of PHC, though the French system is more open to innovative 
market access. cOnclusiOns: If the largest EU health care systems are to secure 
the full benefits of PHC, they will need to provide for full and flexible reimbursement 
for innovative technologies and services based on value. Currently, the importance 
of PHC by health care politicians is not being reflected in the evaluation tools or 
reimbursement methods being applied.
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Objectives: To analyse trends in reimbursement in Ireland to help in the planning 
of HTAs from an industry perspective. MethOds: A database of all NCPE deci-
sions and reimbursement for drugs from 2006 to April 2013 was developed from 
publically available NCPE reports and HSE websites. A descriptive analysis of the 
database was undertaken. Results: From 2006 to April 2013 37% of drugs were 
reimbursed without a HTA and 63% were recommended for HTA (N= 126). There 
were three HTAs undertaken in 2006 compared to 26 in 2012. High Tech (HT) drugs 
were more likely to attract a HTA compared to General Medical Services (GMS) drugs 
(83% vs. 51%). Of the HTAs completed, 57% resulted in a positive reimbursement 
recommendation within a median time from HTA submission to reimbursement 
of 7.9 months (min 3.9, max 16.3). The median time was 7.1 and 9.8 months for 
GMS and HT drugs respectively. Dominance almost perfectly predicted reimburse-
ment; 83% reimbursed. Of the ICERs in the north-east quadrant, 54% resulted in 
a positive reimbursement recommendation (average ICER around € 60,000/QALY). 
The cost per QALY for those not reimbursed in this quadrant was almost twice this 
at around € 110,000. Finally, the average probability of cost effectiveness for reim-
bursed and non-reimbursed drugs were 60% and 30% respectively. cOnclusiOns: 
Companies can expect more requests for HTAs especially for HT drugs. When HTAs 
are requested the probability of success is around 60% with an expected timeline 
of 8 months from submission to launch. Budget impact does have an important 
role to play as dominance is a strong predictor of reimbursement. The average cost 
per QALY for reimbursed drugs is above the € 45,000/QALY threshold but does not 
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recession and the IPHA agreement on the rate of positive reimbursement made by 
the NCPE. We also tested whether the new agreement had an impact on the time-
to-reimbursement using a linear regression model. Results: The results of the 
logit model suggest that neither the economic recession nor the agreement had 
any statistically significant impact on the probability of reimbursement. However, 
there was some evidence that the time-to-reimbursement was reduced after the 
agreement (p< 0.10). cOnclusiOns: Although the analysis suggests that these two 
events had no impact on the rate of reimbursement it is possible that the reimburse-
ment price of new drugs may have decreased over this period which could have 
facilitated reimbursement. Unfortunately, details of the final price of medicines are 
not always known in the Irish system and it is therefore not possible to test this 
hypothesis using currently available data. Our analysis of time-to-reimbursement 
suggests that the new agreement may have satisfied one of its main objectives in 
getting new medicines onto the market sooner.
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Objectives: Offering a standardized HTA process model through economic evalu-
ation of IDTs in the Turkish health care system. MethOds: Current regulations on 
evaluation of innovative drug technologies through the reimbursement process are 
defined via a process flow scheme. A stepwise model is proposed to cover a stand-
ardized HTA system within the economic evaluation through an independent HTA 
body (Model HTA Authority). Results: In the current system, economic evaluation 
content of a reimbursement application dossier is evaluated by Social Security 
Institution (SSI) through Technical and Main Commissions respectively. However 
this evaluation process is not standardized with respect to main variables such as 
scientific methodologies, timelines and responsibilities. This study offers a model, 
which initiates a re-defined application step for economic evaluation content 
of a IDT reimbursement dossier; parallel application to SSI and an independent 
HTA body (Model HTA Authority). Therefore, the Main Commission in SSI will be 
able to combine a general evaluation from the Technical Commission and an HTA 
report of the IDT by an independent HTA body. These reports will be available to 
owners of reimbursement applications until announcement of a final decision of 
SSI, and will become publicly available afterwards. cOnclusiOns: IDTs are not 
involved in a standardized HTA process in the current Turkish health care system. 
However, pharmacoeconomic analysis reports are requested by SSI for reimburse-
ment applications of IDTs. This study offers a model, which includes a standard-
ized HTA process for IDT in the Turkish health care system. Applicability of this 
model may be tested through pilot projects and further steps may be defined for 
further excellence.
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Objectives: To identify, from a private payer’s perspective, the required elements 
to include in a pharmacoeconomic model and a budget impact analysis and com-
pare them to that of the public payers’ requirements. The secondary objective was 
to determine the preferred components to present in a submission regarding pri-
vate payers. MethOds: A survey was sent to 21 submission reviewers from 14 
private insurance companies offering drug reimbursement, using an online sur-
vey builder, KwikSurveys. The survey included 15 questions divided in 5 sections: 
General information, Clinical information, Pharmacoeconomic evaluation, Budget 
impact analysis and General appreciations. Results: Nine reviewers from eight 
different companies, which represent 80% of the Canadian private payer market 
shares, responded to the survey. Results showed that 67% of participants follow the 
Canadian Agency for Drugs and Technologies in Health (CADTH) guidelines for eco-
nomic evaluations. 88% of participants prefer a cost-effectiveness evaluation, while 
75% prefer a cost-benefit evaluation. 100% of the participants would like direct drug 
costs and the indirect costs related to loss of productivity due to reduced working 
capacity to be included in the pharmacoeconomic model. 75% would like the costs 
to employer to hire and train replacement worker, the costs of premiums paid to, 
as well as benefits received from, private insurers to also be included in the model. 
63% of the participants would like to see a population data-based model for their 
budget impact analysis. Similarly, 63% of the participants prefer a time horizon 
of 3 years for the budget impact analysis. cOnclusiOns: The parameters to be 
considered in a submission sent to private payers are different from public payers’ 
requirements. The perspective of the pharmacoeconomic model should be that of 
a private payer and the budget impact analysis should only consider a population 
covered by private payers.
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Objectives: Market access for innovative new technologies can be complex 
and time consuming. As cost-containment pressures in the European Union (EU) 
intensify, evidentiary hurdles to justify new point-of-care (POC) tests continue to 
grow. Decentralized health care decision making can also be a significant hurdle. 
This study aimed to characterize the process and identify challenges for Health 
Technology Assessment (HTA), pricing, reimbursement, and market access for a 
new POC test in the EU-5 countries. MethOds: We conducted desktop research of 
dence. Both organizations reached the same assessment regarding clinical benefit 
in only 13 cases (52%). cOnclusiOns: AMNOG implements a more rigorous process 
with respect to clinical evidence assessment compared to SMC. All AMNOG deci-
sions are positive; however final prices may resemble generic prices for products 
that demonstrate low additional benefit (“Festbetragsgruppen”). In comparison, 
a negative decision by SMC warrants re-submission and re-assessment of the set 
price for successful drug reimbursement. Orphan drugs are assessed as normal 
products in Scotland and may be rejected on the grounds of economic evidence, 
while in Germany the additional benefit is presumed and price negotiation starts 
automatically. Furthermore, the SMC assessment process starts later than the 
AMNOG process.
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While pharmaceutical sales in mature economies are declining, in emerging mar-
kets they have been expanding rapidly, with growth rates in double figures. Here we 
focus on market access in BRIC (Brazil, Russia, India and China) which together rep-
resent just over 40% of the world population.Objectives: To identify the processes 
and key stakeholders involved in gaining market access in BRIC; to assess the impor-
tance of health technology assessment (HTA) in gaining reimbursement in these 
countries; to identify opportunities and challenges to market access. MethOds: 
A review was conducted to identify the current processes and key stakeholders in 
market access in the BRIC countries and to identify favourable and unfavourable fac-
tors to market access. Results: The licensing and reimbursement processes vary 
in the BRIC countries. Brazil follows processes similar to those in Western Europe, 
including HTA and public consultation as part of the reimbursement application. In 
China, the licensing process can take 4-6 years, though fast-tracking for innovative 
drugs has recently been introduced. Russia, China and India do not yet rely on HTA 
for reimbursement decisions. In India plans to use “pharmacoeconomic principles” 
in setting prices of new molecules have been announced. Opportunities in all these 
countries result from increasing affluence and life expectancy and the diseases 
associated with these. Some challenges to market access are: poor IP protection; 
protectionist measures; compulsory licensing; drive to use generics or biosimilars, 
often produced locally; price controls; variable health insurance/NHS coverage; 
and limited budgets for prescription drugs. cOnclusiOns: HTA is now common 
practice in Brazil, but not yet in Russia, India or China. Although demand for new 
drugs is increasing in these markets, protectionism measures, competition from 
generics and budget constraints due to the increased burden and requirement for 
new high priced drugs present a challenge when accessing the pharmaceutical 
market in BRIC countries.
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Objectives: The gold-standard pivotal trial design has three arms with experi-
mental medicine, placebo and active control however, often marketing authorisa-
tion is granted on placebo controlled (PLAc) trial(s). While PLAc trials are often 
still acceptable to the European Clinical Trials Directive and European Medicines 
Agency (EMA), they are less acceptable to Health Technology Assessment (HTA) 
bodies. The latter request an (in)direct comparison vs. the relevant active 
comparator(s) (AC) to demonstrate the added value of existing standard of care. 
We have investigated the hurdles encountered during HTA assessments for those 
drugs with marketing authorization based solely on PLAc studies. MethOds: We 
identified those drugs approved since 2010 by EMA based only on PLAc trials. We 
then reviewed the HTA assessments for these drugs in France (HAS), Germany 
(G-BA) and the UK (NICE and SMC) and compared these HTA assessments to others 
where the trial included an AC. Results: Applications for 41 (45 indications) of the 
220 drugs approved by EMA between 2010 and end of 2012 were based exclusively 
on PLAc trials. The number of indications already assessed and recommended 
(percentage) by HTA bodies are 19 and 11 (58%) for NICE, 33 and 18 (55%) for SMC, 
24 and 20 (83%) for HAS, and 18 and 12 (67%) for G-BA. When compared to all 
HTAs irrespective of comparator being placebo or AC assessed since 2010, lack of 
an AC seemed to have no impact in HAS (83% vs 75% favorable opinion among all 
assessments) and G-BA (67% vs 58%) assessments but had a negative impact on 
SMC (55% vs 85%) and NICE (58% vs 64%) recommendations. cOnclusiOns: The 
impact of no direct comparison with an AC varies across countries. The analysis 
seems to indicate that in absence of head-to-head data HTA agencies will accept 
indirect evidence against the right AC.
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Objectives: To assess the impact of the Irish economic recession (September, 2008) 
and the Irish Pharmaceutical Healthcare Association agreement (IPHA; November, 
2012) on the probability of reimbursement decided by the National Centre for 
Pharmacoeconomic Evaluation (NCPE). We also aim to test whether the new IPHA 
agreement reduced the time-to-reimbursement for new medicines in the General 
Medical Services (GMS) and High Tech Drug Scheme (HTDS). MethOds: A database 
of all NCPE decisions since 2006 to present was compiled from publically available 
NCPE decision reports and a logistic model was used to test the occurrence of the 
